3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD

Celeste Porsbjerg*, Anke H Maitland-van der Zee, Guy Brusselle, Giorgio Walter Canonica, Alvar Agusti, Rosa Faner, Claus F Vogelmeier, Martijn Nawijn, Maarten van den Berge, Franca Rusconi, Charles Pilette, Valeria Ramiconi, Courtney Coleman, Rekha Chaudhuri, Kian Fan Chung, Jadwiga Wedzicha, Sejla Saglani, Marc P Van der Schee, Liam Heaney, Arnaud BourdinGraham Roberts, Ratko Djukanovic, Piotr Kuna, Maceij Kupczyk, Judith Axmann, Heribert Staudinger, Graham W Clarke, Sven Erik Dahlen, Chris Brightling

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

18 Downloads (Pure)

Abstract

3TR, the largest IMI consortium ever in immune diseases, brings clinical researchers and scientists from several disease areas together, in an endeavour to increase the clinical impact of targeted immune-mediated therapies, including asthma and COPD.
Original languageEnglish
Article number2102168
Number of pages7
JournalEuropean Respiratory Journal
Volume58
Issue number4
DOIs
Publication statusPublished - Oct-2021

Keywords

  • Asthma/drug therapy
  • Cross-Sectional Studies
  • Humans
  • Pulmonary Disease, Chronic Obstructive/drug therapy

Cite this